A Systems Biology- and Machine Learning-Based Study to Unravel Potential Therapeutic Mechanisms of Midostaurin as a Multitarget Therapy on FLT3-Mutated AML
Authors:
- Marina Díaz-BeyáMDMarina Díaz-Beyá
- María García-FortesMGMaría García-Fortes
- Raquel VallsRVRaquel Valls
- Laura ArtigasLALaura Artigas
- Mª Teresa Gómez-CasaresMGMª Teresa Gómez-Casares
- Pau MontesinosPMPau Montesinos
- Fermín Sánchez-GuijoFSFermín Sánchez-Guijo
- Mireia ComaMCMireia Coma
- Meritxell VendranesMVMeritxell Vendranes
- Joaquín Martínez-LópezJoaquín Martínez-López
Open Access
- 25 July 2022
- journal article
- research article
- Published by MDPI AG in BioMedInformatics
- Vol. 2 (3) , 375-397
Abstract
Acute myeloid leukemia (AML), a hematologic malignancy that results in bone marrow failure, is the most common acute leukemia in adults. The presence of FMS-related tyrosine kinase 3 (FLT3) mutations is associated with a poor prognosis, making the evaluation of FLT3-inhibitors an imperative goal in clinical trials. Midostaurin was the first FLT3-inhibitor approved by the FDA and EMA for the treatment of FLT3-mutated AML, and it showed a significant improvement in overall survival for newly diagnosed patients treated with midostaurin, in combination with standard chemotherapy (RATIFY study). The main interest of midostaurin has been the FLT3-specific inhibition, but little is known about its role as a multikinase inhibitor and whether it may be used in relapse and maintenance therapy. Here, we used systems biology- and machine learning-based approaches to deepen the potential benefits of the multitarget activity of midostaurin and to better understand its anti-leukemic effect on FLT3-mutated AML. The resulting in silico study revealed that the multikinase activity of midostaurin may play a role in the treatment’s efficacy. Additionally, we propose a series of molecular mechanisms that support a potential benefit of midostaurin as a maintenance therapy in FLT3-mutated AML, by regulating the microenvironment. The obtained results are backed up using independent gene expression data.Keywords
Funding Information
- Novartis Spain
This publication has 79 references indexed in Scilit:
- Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem CellsScience Translational Medicine, 2010
- SMPDB: The Small Molecule Pathway DatabaseNucleic Acids Research, 2009
- Structural and Functional Alterations of FLT3 in Acute Myeloid LeukemiaClinical Cancer Research, 2009
- Dysregulated gene expression networks in human acute myelogenous leukemia stem cellsProceedings of the National Academy of Sciences, 2009
- Human Protein Reference Database--2009 updateNucleic Acids Research, 2008
- DrugBank: a knowledgebase for drugs, drug actions and drug targetsNucleic Acids Research, 2007
- The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic studyBritish Journal of Cancer, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- Gene Expression Omnibus: NCBI gene expression and hybridization array data repositoryNucleic Acids Research, 2002
- KEGG: Kyoto Encyclopedia of Genes and GenomesNucleic Acids Research, 2000